CRISPR Therapeutics AG (CRSP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350M 700M 1.1B Q3 '21: 902.4M Q4 '21: 915M Q1 '22: 915.4M Q2 '22: 14.8M Q3 '22: 14.1M Q4 '22: 1.2M Q1 '23: 100.3M Q2 '23: 170.1M Q3 '23: 170M Q4 '23: 371.2M Q1 '24: 271.7M Q2 '24: 202.2M Q3 '24: 202.8M Q4 '24: 37.3M Q1 '25: 37.7M Q2 '25: 38M Q3 '25: 38.3M Q4 '25: 3.5M Q1 '26: 4.1M Q2 '26: 13.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: 411.5M Q4 '21: 373.5M Q1 '22: 312.1M Q2 '22: -633.8M Q3 '22: -687.3M Q4 '22: -673.2M Q1 '23: -561.7M Q2 '23: -473.6M Q3 '23: -423.7M Q4 '23: -222.5M Q1 '24: -298.6M Q2 '24: -354.7M Q3 '24: -332.4M Q4 '24: -466.6M Q1 '25: -474.4M Q2 '25: -552.5M Q3 '25: -574.4M Q4 '25: -664.6M Q1 '26: -646.4M Q2 '26: -534.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: 411.9M Q4 '21: 377.7M Q1 '22: 311.6M Q2 '22: -633.5M Q3 '22: -680.8M Q4 '22: -650.2M Q1 '23: -524M Q2 '23: -415.9M Q3 '23: -353.5M Q4 '23: -153.6M Q1 '24: -217.1M Q2 '24: -265.8M Q3 '24: -239.6M Q4 '24: -366.3M Q1 '25: -385.7M Q2 '25: -467.8M Q3 '25: -488.3M Q4 '25: -581.6M Q1 '26: -568.5M Q2 '26: -451.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: 543.8M Q4 '21: 539M Q1 '22: 504.4M Q2 '22: -444.6M Q3 '22: -468.5M Q4 '22: -495.7M Q1 '23: -351.7M Q2 '23: -343M Q3 '23: -277.6M Q4 '23: -260.4M Q1 '24: -159.4M Q2 '24: -121.8M Q3 '24: -188.8M Q4 '24: -142.8M Q1 '25: -306.5M Q2 '25: -324.8M Q3 '25: -302.5M Q4 '25: -345M Q1 '26: -400M Q2 '26: -369.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: 465M Q4 '21: 457.3M Q1 '22: 414.4M Q2 '22: -515.8M Q3 '22: -508.6M Q4 '22: -532.9M Q1 '23: -376.6M Q2 '23: -361.8M Q3 '23: -292.6M Q4 '23: -269.8M Q1 '24: -166.6M Q2 '24: -126M Q3 '24: -191.2M Q4 '24: -144.7M Q1 '25: -307.9M Q2 '25: -325.6M Q3 '25: -303.1M Q4 '25: -345.9M Q1 '26: -401.2M Q2 '26: -371.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '20: 61.4M Q3 '20: 70.1M Q4 '20: 71.3M Q1 '21: 75M Q2 '21: 80.4M Q3 '21: 76.3M Q1 '22: 77.1M Q2 '22: 77.5M Q3 '22: 78M Q1 '23: 78.7M Q2 '23: 79.1M Q3 '23: 79.4M Q1 '24: 81.8M Q2 '24: 84.9M Q3 '24: 85.2M Q1 '25: 85.9M Q2 '25: 87.1M Q3 '25: 91.3M Q1 '26: 96.1M Q2 '26: 96.5M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q3 '21: 4.76 Q4 '21: 4.70 Q1 '22: 3.89 Q2 '22: -7.95 Q3 '22: -8.52 Q4 '22: -8.36 Q1 '23: -6.71 Q2 '23: -5.29 Q3 '23: -4.46 Q4 '23: -1.94 Q1 '24: -2.70 Q2 '24: -3.21 Q3 '24: -2.81 Q4 '24: -4.35 Q1 '25: -4.50 Q2 '25: -5.41 Q3 '25: -5.57 Q4 '25: -6.50 Q1 '26: -6.20 Q2 '26: -4.74 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.